The Potential  Risk of Gene Therapies  includes :- Potential for Allergic Reactions * Inflammation * Unknown Long Health Effects – Consequences * Concerns around the risks of Integrating Vectors. Hene Therapies can lead to Severe Health Problems. Long Term follow-up is Crucial

1)Long Term Risks of Integrating Vectors Gene Therapies include:- Insertional Mutagenesis leading to Secondary Malignancies * Immune Related Reactions * Persistent Infections. Although newer Vectors have been developed it is still reported that its crucial, essential for long term monitoring  * Insertional Mutagenesis: Integrating vectors can insert in or near genes that regulate cell growth, potentially causing uncontrolled cell growth and secondary cancers, as seen in early leukemia cases from some retroviral therapy trials

1a) Gene Disruptions: Integration can sometimes disrupt essential Genes or regulatory elements, leading to impaired Gene function  *Gene Editing Tools like CRISPA-Cas 9 can cause unintended modifications, such as Large Deletions or Chromosomal Rearrangements

2)There Are Also Immune Related Risks such as Autoimmune Reactions: where the body’s Immune System may recognize the Vector or the new Therapeutic Protein as Foreign thus triggering an Immune Response that can lead to Autoimmune like conditions also an

2a)Immune Suppression or Over-stimulation is a risk- where Immune Responses can be Unpredictable. In some cases the Immune Response can reduce the Therapy’s effectiveness or cause Systemic Inflammation

2b) Hypersensitivity can happen when introducing new Proteins from Gene Therapies, this can lead to hypersensitivity or, in rare cases, anaphylaxis.

3a)Viral/Bacterial Vector Risks: May include a ‘Persistent Infection as some Viral or Bacterial Vectors can cause persistent, long term infections, particularly in immune-compromised individuals.

3b)Re-Activation problems may occur as Vectors with a potential for Latency can Re-activate later thus leading to ‘Delayed Adverse Events’

3c) The Random Nature of Vector Integration can lead to other Genetic Errors beyond Oncogenesis, with unpredictable Long Term Consequences

4)Why is Long Term Monitoring Crucial? Because Permanent Changes can happen by Integrating Gene Therapies which are designed to provide Long Term or Permanent Therapeutic effects.. which is why the potential for unpredictable- delayed risks like Malignancy is a real concern…

5)Due to the potential for Serious Delayed Adverse Events – Long Term Follow-up is required to Monitor for these Risks  *Ongoing Research is critical for better understanding of these risks for developing much safer therapies. There are still many uncertainties.

6) Long-term gene control: For lifelong therapies, controlling the expression level of the integrated gene is critical, but this can be difficult to manage consistently over a patient’s lifetime.

7) Non-Integrating Vectors (Adeno- Associated Viral Vectors): AAV vectors deliver their genes as small, circular DNA molecules called episomes that stay in the cell nucleus – however:-

8)Pre-Existing Immunity can happen because AAV is common in the wild, many people have pre-existing antibodies that can neutralize the Vector, rendering the Therapy ineffective or causing Toxic Immune reactions. Acute Immunotoxicity is a risk although less immunogenic than some other Vectors, high dose Systemic AVV Therapy has been linked to Severe and sometimes Fatel Immunotoxicities eg :- Liver * Kidney and Heart Failure..* These adverse reactions are due to strong immune responses that can be difficult to predict or treat.

9)Dorsal Root Ganglion (DRG Toxicity): Some AAV serotypes can cause neurotoxicity in the peripheral nervous system, particularly when delivered intrathecally (into the spinal fluid).

10)Integration Risks: AAV Vectors can integrate into the Host at low frequency. Animal studies have occasionally linked this to the development of hepatocellular carcinoma, though this risk appears to be largely theoretical in human clinical settings.. There can be a risk of Transient Expression because Episomal DNA is not passed during Cell Division, the therapeutic effect can be diluted over time, particularly in tissues with high cell turnover.

11)The Long-Term Considerations For All Vectors:-

11a) Autoimmune reactions: The expression of a new protein by the vector could be misinterpreted as foreign by the immune system, potentially leading to autoimmune-like disorders.

11b) Infection and latency: Vector components from herpes viruses can have potential for latency and reactivation

11c) Patient monitoring: The long-term nature of these therapies necessitates long-term follow-up for treated patients to ensure safety, durability, and effectiveness. The FDA may require multi-year or multi-decade monitoring, especially for products with high integration activity or those intended for permanent effects.

12)WHAT IS A VECTOR IN GENE THERAPY?:  A Vector in Gene Therapy is a Delivery Vehicle used to Transport Therapeutic Genetic Material into a Patients Cells. The goal is to correct a defective gene, add a new one, or manipulate gene expression to treat or prevent a disease.

13)How do Vectors Work? Vectors are engineered to overcome the natural cellular barriers that prevent foreign genetic material from entering a cell. They act like tiny envelopes or packages, carrying their genetic payload to the target cells. Upon arrival, the vector unloads its cargo, which is then replicated and/or expressed to produce the desired therapeutic effect.

13a) What Types of Vectors are there?…. Vectors are broadly categorized into two main types: viral and non-viral…

13b) There are Viral Vectors:- These are modified viruses, stripped of their disease-causing genes and engineered to carry therapeutic genes instead. Viruses are highly effective as vectors because they have naturally evolved efficient mechanisms for infecting cells and delivering their genetic material. Common types include

13c) Lentiviruses and Retroviruses: Derived from viruses like HIV, these vectors are notable for their ability to integrate the therapeutic gene permanently into the host cell’s genome, allowing for long-term gene expression. Lentiviruses can target both dividing and non-dividing cells.

14)Adeno-Associated Viruses (AAVs) ..These are used widely because they are non-pathogenic (not known to cause disease) and have a low risk of triggering a strong immune response. They typically deliver genes as separate, non-integrating DNA molecules (episomes), which can lead to durable expression in long-lived, non-dividing cells.

15) Adenoviruses: Based on the common cold virus, these vectors can carry a large genetic payload and deliver genes to a wide variety of cells. The genetic material is not integrated into the host genome, leading to temporary expression.

16) Non-viral Vectors: These are artificial or synthetic delivery systems that avoid the potential safety issues associated with viruses. While often safer, they can be less efficient at delivering genes than viral vectors. Non-viral vectors include….

16a) Lipid Nanoparticles (LNPs): These are tiny, synthetic fat-like particles that can encapsulate genetic material like DNA or mRNA. This approach was famously used for the delivery of mRNA in COVID-19 vaccines.

16b) Physical methods: Techniques like electroporation and the “gene gun” use physical force, such as electrical pulses or pressure, to create temporary openings in the cell membrane, allowing genetic material to enter.

16c) Polymer-based vectors: Positively charged polymers can bind to negatively charged DNA, forming a complex that protects the genetic cargo and helps it enter the cell

17)What Is The Purpose of Using Vectors? Vectors are necessary for several key reasons in gene therapy. Vectors are used for Protection * Targeting *Overcoming barriers. For instance…..

17a)  (1)They protect the delicate genetic material from being degraded by the body’s enzymes before it can reach its target. (2) They can be engineered to Target specific Cell Types thus increasing the therapy’s precision and reducing potential side effects on healthy cells.  (3) When it comes to ‘Overcoming barriers they help the Genetic Cargo Cellular Barriers, such as the Cell Membrane and Nuclear Envelope to reach its Site of Action

18)CONCLUSION:  The Main Dangers Of Gene Therapy: Are a harmful immune response, the potential for causing cancer, and unintended side effects from gene delivery. While gene therapy holds immense promise for treating diseases, these risks underscore the need for careful vector design, patient screening, and long-term monitoring.

19)Several 2025 reports and events indicate that gene therapy, while making significant progress, continues to carry potential risks. Issues such as acute toxicities, adverse immune responses, and the complexities of long-term follow-up and manufacturing have been highlighted in clinical trial updates, regulatory guidance, and market analysis throughout the year.

20)Recent Clinical Trials have  underscored that severe, acute adverse events remain a risk for certain gene therapy products.. For Example- n 2025, regulatory and public attention focused on Sarepta Therapeutics’ approved Duchenne muscular dystrophy gene therapy, Elevidys. In July 2025, the FDA requested the suspension of all Elevidys distribution and placed a clinical hold on related trials after a third patient died, likely due to acute liver failure.

20a)Because of Vector-related issues: The fatal events for Elevidys were associated with the AAVrh74 vector, prompting the FDA to suspend its platform designation for that vector. This indicates that even with standardized vectors, severe and sometimes fatal toxicities can arise

20b)It was Highlighted in several 2025 Reports that Managing the Patients Immune Response to Viral Vector remains a Challenge…A presentation at the American Society of Gene and Cell Therapy (ASGCT) 2025 conference discussed a gene therapy for osteoarthritis. It noted that patients with pre-existing antibodies to the AAV vector showed less improvement than those without, demonstrating how prior immunity can limit treatment effectiveness.

20c)In a June 2025 Article Researchers noted that severe inflammatory reactions to viral proteins, which can lead to organ damage, remain a concern.  * Because gene therapies are often intended to produce permanent or long-lasting changes, the need for long-term monitoring is ongoing and complex.

21)Delayed Adverse Events – (A FDA Draft Guidance Document from January 2025).. emphasizes that patients in gene therapy trials may be at risk for undesirable outcomes that appear as delayed adverse events. Depending on the product, the guidance recommends monitoring subjects for up to 15 years.

22)Reference has been made to new Disease Patterns: At the World Federation of Neurology congress in October 2025, Professor Mary Reilly noted that as patients live longer, novel disease patterns may emerge, emphasizing the need to study the natural history of treated diseases.

23)The Evolving Regulatory Environment:- Regulatory bodies like the FDA are continually adapting their standards to balance innovation with patient safety, indicating that the landscape is not yet settled.

  24) Call for Stricter Standards: Throughout 2025, the FDA  has signaled stricter evidentiary standards for gene therapy approvals. The agency has been willing to extend review timelines to gather more long-term durability data before giving final approval

25)September and October 205 the FDA released a new draft guidance documents for Clinical Trials covering innovative trial designs for rare diseases and post-approval safety data collection for gene therapies. This shows an ongoing effort to address the unique challenges of gene therapy, rather than viewing the safety issues as fully resolved.

26)There is a Commercial and Investment Risk:

26a)Risk perception: A 2025 report from the consulting firm McKesson found that two-thirds of oncologists still view cell and gene therapies (CGTs) as “largely unproven,” and 66% say their patients see CGTs as “too experimental or risky”.

26 b)Cost and reimbursement: Insurers in 2025 have continued to demand more evidence to justify reimbursement for gene therapies, which, along with recent safety incidents, has contributed to a downturn in investment in the sector

WakeUpNZ

RESEARCHER: Cassie